Semaglutide cut heavy drinking days in first randomized GLP-1 trial for alcohol use disorder, NIH says

Weekly semaglutide combined with cognitive behavioral therapy lowered heavy drinking days in adults who have both alcohol use disorder and obesity, the National Institutes of Health announced on April 30, 2026 ^[1]. According to the agency, it is the first evidence from a randomized controlled trial that a GLP-1 receptor agonist can reduce heavy drinking in this population ^[1].

The 26-week study enrolled 108 people seeking treatment for alcohol use disorder who also had obesity. All of them received standard cognitive behavioral therapy and were assigned at random to get either a weekly dose of semaglutide or a placebo, with neither participants nor researchers knowing which, the announcement states ^[1].

Heavy drinking days dropped 41.1% in the semaglutide group, a reduction 13.7 percentage points larger than the one seen with placebo ^[1]. Blood-based biomarkers of drinking supported the self-reported results, the agency said ^[1]. The trial was published in The Lancet and was led by first author Mette Kruse Klausen, M.D., and corresponding author Anders Fink-Jensen, D.M.Sc., at Copenhagen University Hospital, working with NIH scientists and international colleagues ^[1].

The researchers reported a number needed to treat of 4.3, a measure of how many patients must be treated for one to gain a benefit. For medications already approved for alcohol use disorder, that figure is 7 or higher, the announcement says ^[1].

"Very few medications are currently approved for alcohol use disorder, and these are vastly underutilized. A new option that is more accessible and more effective could be a gamechanger for closing the treatment gap," said National Institute on Alcohol Abuse and Alcoholism director George Koob, Ph.D., a study co-author ^[1]. Nora Volkow, M.D., director of NIH's National Institute on Drug Abuse and another co-author, said researchers are "beginning to see some of that potential for GLP-1s to treat drug addiction turn into reality," adding that questions remain ^[1].

Declines in body weight, blood pressure and other clinical measures were bigger in the semaglutide group, which the authors described as expected. Reported side effects included gastrointestinal symptoms, which the authors said were transient and mild ^[1]. The announcement does not provide the placebo group's own reduction figure, and the dose of semaglutide used has not been disclosed ^[1].

An earlier clinical trial found no effect on heavy drinking when its whole study group was analyzed, but a strong response in the subset of participants who had obesity ^[1]. The new trial enrolled only patients with obesity ^[1].

Why it matters for patients

Alcohol use disorder has few approved medications, and the announcement notes that those are vastly underutilized ^[1]. Semaglutide is already widely prescribed for weight loss, so a new use here would involve a drug many patients and clinicians already know.

The findings come from one 108-person trial in which every participant also received cognitive behavioral therapy ^[1]. They do not show what semaglutide does without therapy, or in people who are not seeking treatment. Whether drinking reductions last after a person stops the medication was not reported, and it has not been reported whether the effect depends on dose or on how much weight someone loses.

No head-to-head comparison with medications already approved for alcohol use disorder was reported, so relative effectiveness is not established ^[1]. The announcement describes alcohol use disorder as a potential use for semaglutide; it is not an approved one, and no regulatory filing or label change has been announced.

What happens next

The authors say they want to examine GLP-1s over a longer duration and in a larger population to confirm these results ^[1]. No dates, sizes or locations for such follow-up studies have been disclosed, and no timeline for a possible regulatory submission has been announced.